Diminished synaptic gain—the sensitivity of postsynaptic responses to neural inputs—may be a fundamental synaptic pathology in schizophrenia. Evidence for this is indirect, however. Furthermore, it is unclear whether pyramidal cells or interneurons (or both) are affected, or how these deficits relate to symptoms. People with schizophrenia diagnoses (PScz) (n = 108), their relatives (n = 57), and control subjects (n = 107) underwent 3 electroencephalography (EEG) paradigms—resting, mismatch negativity, and 40-Hz auditory steady-state response—and resting functional magnetic resonance imaging. Dynamic causal modeling was used to quantify synaptic connectivity in cortical microcircuits. Classic group differences in EEG features between PScz and control subjects were replicated, including increased theta and other spectral changes (resting EEG), reduced mismatch negativity, and reduced 40-Hz power. Across all 4 paradigms, characteristic PScz data features were all best explained by models with greater self-inhibition (decreased synaptic gain) in pyramidal cells. Furthermore, disinhibition in auditory areas predicted abnormal auditory perception (and positive symptoms) in PScz in 3 paradigms. First, characteristic EEG changes in PScz in 3 classic paradigms are all attributable to the same underlying parameter change: greater self-inhibition in pyramidal cells. Second, psychotic symptoms in PScz relate to disinhibition in neural circuits. These findings are more commensurate with the hypothesis that in PScz, a primary loss of synaptic gain on pyramidal cells is then compensated by interneuron downregulation (rather than the converse). They further suggest that psychotic symptoms relate to this secondary downregulation.
Background Group testing, combining the samples of multiple patients into a single pool to be tested for infection, is an approach to increase throughput in clinical diagnostic and population testing by reducing the number of tests required. In order to further increase the throughput and accuracy of these approaches, mathematicians regularly devise novel combinatorial methods. However, although these novel methods are easily validated in silico, they are often never implemented in diagnostic laboratories because of the lack of clear and standardised pathways to clinical validation. Methods We develop a standardised analytical workflow that makes use of high-throughput automation and virus-like particle standards to validate theoretical group testing approaches. We then utilise specially developed virus-like particles for SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) to develop and validate a novel multiplex group testing approach based on simulated annealing and Bayesian optimization. Our approach improves the inference of positive samples in group testing, leveraging the quantitative nature of RT-qPCR test results. Results Our results show a higher positive predictive value of our novel approach for the inference of positive samples compared to the standard approach using binary test outcomes. In large-scale surveillance testing our method can greatly reduce the number of false positive identifications. Our in vitro findings show the viability of group testing for multiplexed testing of respiratory infections and demonstrate the potential of a novel inference method. Both innovations increase the number of people that can be tested with the available resources, which is particularly important in low-resource settings.